Skip to main content
Log in

Drug-Induced Diarrhoea

Drug Safety Aims and scope Submit manuscript

Abstract

Diarrhoea is a relatively frequent adverse event, accounting for about 7% of all drug adverse effects. More than 700 drugs have been implicated in causing diarrhoea; those most frequently involved are antimicrobials, laxatives, magnesium-containing antacids, lactose- or sorbitol-containing products, nonsteroidal anti-inflammatory drugs, prostaglandins, colchicine, anti-neoplastics, antiarrhythmic drugs and cholinergic agents. Certain new drugs are likely to induce diarrhoea because of their pharmacodynamic properties; examples include anthraquinone-related agents, α-glucosidase inhibitors, lipase inhibitors and cholinesterase inhibitors. Antimicrobials are responsible for 25% of drug-induced diarrhoea. The disease spectrum of antimicrobial-associated diarrhoea ranges from benign diarrhoea to pseudomembranous colitis.

Several pathophysiological mechanisms are involved in drug-induced diarrhoea: osmotic diarrhoea, secretory diarrhoea, shortened transit time, exudative diarrhoea and protein-losing enteropathy, and malabsorption or maldigestion of fat and carbohydrates. Often 2 or more mechanisms are present simultaneously.

In clinical practice, 2 major types of diarrhoea are seen: acute diarrhoea, which usually appears during the first few days of treatment, and chronic diarrhoea, lasting more than 3 or 4 weeks and which can appear a long time after the start of drug therapy. Both can be severe and poorly tolerated.

In a patient presenting with diarrhoea, the medical history is very important, especially the drug history, as it can suggest a diagnosis of drug-induced diarrhoea and thereby avoid multiple diagnostic tests. The clinical examination should cover severity criteria such as fever, rectal emission of blood and mucus, dehydration and bodyweight loss. Establishing a relationship between drug consumption and diarrhoea or colitis can be difficult when the time elapsed between the start of the drug and the onset of symptoms is long, sometimes up to several months or years.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Table I
Table II

Similar content being viewed by others

References

  1. Bramble MG, Record CO. Drug-induced gastrointestinal disease. Drugs 1978; 15: 451–63

    Article  PubMed  CAS  Google Scholar 

  2. Johnson RA. Adverse reactions in ten years’ general practice, computer-analysed. J R Soc Med 1986; 79: 143–6

    Google Scholar 

  3. Beaugerie L, Gendre JP. Drug-induced colitis. Med Hyg 1993; 51: 2153–5

    Google Scholar 

  4. Fine KD. Diarrhea. In: Feldman M, Scharschmidt BF, Sleisenger MH, editors. Sleisenger and Fordtran’s gastrointestinal and liver disease: pathophysiology, diagnosis, management. 6th ed. Philadelphia: WB Saunders, 1998: 128-52

  5. Micromedex Inc. Micromedex Healthcare Series New Integrated Index™ [online document]. Available from: http://www.micromedex.com [accessed 1999 Nov 22]

  6. Pariente EA. Drug-induced enteropathies. Gastroenterol Clin Biol 1982; 6: 16–8

    PubMed  CAS  Google Scholar 

  7. Ratnaike RN, Jones TE. Mechanisms of drug-induced diarrhoea in the elderly. Drugs Aging 1998; 13: 245–53

    Article  PubMed  CAS  Google Scholar 

  8. Longstreth GF, Newcomer AD. Drug-induced malabsorption. Mayo Clin Proc 1975; 50: 284–93

    PubMed  CAS  Google Scholar 

  9. Riddell RH, Tanaka M, Mazzoleni G. Non-steroidal anti-inflammatory drugs as a possible cause of collagenous colitis: a case-control study. Gut 1992; 33: 683–6

    Article  PubMed  CAS  Google Scholar 

  10. Giardiello FM, Hansen FC, Lazenby AJ, et al. Collagenous colitis setting of non steroidal anti-inflammatory drugs and antibiotics. Dig Dis Sci 1990; 35: 257–60

    Article  PubMed  CAS  Google Scholar 

  11. Beaugerie L, Luboinski J, Brousse N, et al. Drug-induced lymphocytic colitis. Gut 1994; 35: 426–8

    Article  PubMed  CAS  Google Scholar 

  12. Duncan HD, Talbot IC, Silk DB. Collagenous colitis and cimetidine. Eur J Gastroenterol Hepatol 1997; 9: 819–20

    Article  PubMed  CAS  Google Scholar 

  13. Berrebi D, Sautet A, Flejou JF, et al. Ticlopidine induced colitis: a histopathological study including apoptosis. J Clin Pathol 1998; 51: 280–3

    Article  PubMed  CAS  Google Scholar 

  14. Yaziji N, Rassiat E, Michiels C, et al. Modopar-induced lymphocytic colitis. Ann Pathol 1996; 16: 25

    Google Scholar 

  15. Bouchet-Laneuw F, Deplaix P, Dumollard JM, et al. Chronic diarrhea secondary to tardyferon and associated to lymphocytic colitis. Gastroenterol Clin Biol 1997; 21: 83–4

    PubMed  CAS  Google Scholar 

  16. Anttila VJ, Valtonen M. Carbamazepine-induced eosinophilic colitis. Epilepsia 1992; 33: 119–21

    Article  PubMed  CAS  Google Scholar 

  17. Chagnon JP, Cerf M. Simvastatin-induced protein-losing enteropathy. Am J Gastroenterol 1992; 87: 257

    PubMed  CAS  Google Scholar 

  18. Bo-Linn GW, Vendrell DD, Lee E, et al. An evaluation of the significance of microscopic colitis in patients with chronic diarrhea. J Clin Invest 1985; 75: 1559–69

    Article  PubMed  CAS  Google Scholar 

  19. Weber DJ, Tolkoff-Rubin NE, Rubin RH. Amoxicillin and potassium clavulanate: an antibiotic combination: mechanism of action, pharmacokinetics, antimicrobial spectrum, clinical efficacy and adverse effects. Pharmacotherapy 1984; 4: 122–36

    PubMed  CAS  Google Scholar 

  20. Gales MA, Gales BJ. Recognition of severe cefixime-induced diarrhea. Clin Pharm 1993; 12: 881

    PubMed  CAS  Google Scholar 

  21. Schwartzberg JE, Maresca RM, Remington JS. Gastrointestinal side effects associated with clindamycin. 1000 consecutive patients. Arch Intern Med 1976; 136: 876–9

    Article  Google Scholar 

  22. Bauwens JE, McFarland LV, Melcher MJ, et al. Recurrent Clostridium difficile disease following ciprofloxacin use. Ann Pharmacother 1997; 31: 1090

    PubMed  CAS  Google Scholar 

  23. Periti P, Mazzci T, Mini E, et al. Adverse effects of macrolide antibacterials. Drug Saf 1993; 9: 346–64

    Article  PubMed  CAS  Google Scholar 

  24. Bartlett JG. Antibiotic-associated diarrhea. Clin Infect Dis 1992; 15: 573–81

    Article  PubMed  CAS  Google Scholar 

  25. Nord CE, Heimdahl A, Kager L. Antimicrobial induced alterations of the human oropharyngeal and intestinal microflora. Scand J Infect Dis 1986; 49Suppl.: 64–72

    CAS  Google Scholar 

  26. McFarland LV. Risk factors for antibiotic-associated diarrhea. Ann Med Interne 1998; 149: 261–6

    CAS  Google Scholar 

  27. Rao SSC, Edwards CA, Austen CJ, et al. Impaired colonic fermentation of carbohydrate after ampicillin. Gastroenterology 1988; 94: 928–32

    PubMed  CAS  Google Scholar 

  28. Clausen MR, Bonnen H, Tvede M, et al. Colonic fermentation to short-chain fatty acids is decreased in antibiotic associated diarrhea. Gastroenterology 1991; 101: 1497–504

    PubMed  CAS  Google Scholar 

  29. Cerny A. Side effects and consequences of frequently used antibiotics in clinical practice. Schweiz Med Wochenschr 1996; 126: 528–34

    PubMed  CAS  Google Scholar 

  30. Jaimes EC. Lincocinamides and the incidence of antibiotic-associated colitis. Clin Ther 1991; 13: 270–80

    PubMed  CAS  Google Scholar 

  31. Thompson JW, Jacobs RF. Adverse effects of newer cephalosporins. Drug Saf 1993; 9: 132–42

    Article  PubMed  CAS  Google Scholar 

  32. Moskovitz BL. Clinical adverse effects during ceftriaxone therapy. Am J Med 1984; 77(Suppl C): 84–8

    PubMed  CAS  Google Scholar 

  33. Job ML, Jacobs NF. Drug-induced Clostridium difficile-associated disease. Drug Saf 1997; 17: 37–46

    Article  PubMed  CAS  Google Scholar 

  34. Pothoulakis C. Pathogenesis of Clostridium difficile-associated diarrhoea. Eur J Gastroenterol Hepatol 1996; 8: 1041–7

    Article  PubMed  CAS  Google Scholar 

  35. Rolfe RD, Finegold SM. Intestinal beta-lactamase activity in ampicillin-induced Clostridium difficile associated ileocolitis. J Infect Dis 1983; 147: 227–35

    Article  PubMed  CAS  Google Scholar 

  36. Tedesco FJ. Ampicillin-associated diarrhea. A prospective study. Am J Dig Dis 1975; 4: 295–7

    Article  Google Scholar 

  37. Toffler RB, Pingoud EG, Burrel MI. Acute colitis related to penicillin and penicillin derivatives. Lancet 1978; II: 707–9

    Article  Google Scholar 

  38. Werth B, Kobler E, Reinhart WH, et al. Clostridium difficile associated diarrhea in cephalosporin administration: experiences of the Swiss adverse drug reaction reporting system 1981-1995. Schweiz Med Wochenschr 1997; 89Suppl.: 5–8

    Google Scholar 

  39. Tedesco FJ, Barton RW, Alpers DH. Clindamycin associated colitis. Ann Intern Med 1974; 81: 429–33

    PubMed  CAS  Google Scholar 

  40. Fekety R. Guidelines for the diagnosis and management of Clostridium difficile-associated diarrhea and colitis. Am J Gastroenterol 1997; 92: 739–50

    PubMed  CAS  Google Scholar 

  41. Tabaqchali S, Jumaa P. Diagnosis and management of Clostridium difficile infection. BMJ 1995; 310: 1375–80

    Article  PubMed  CAS  Google Scholar 

  42. Rubin MS, Bodenstein LE, Kent KC. Severe Clostridium difficile colitis. Dis Colon Rectum 1995; 38: 350–4

    Article  PubMed  CAS  Google Scholar 

  43. Maignan M, Schuhmacher H, Pierfitte C, et al. Pseudo-membranous colitis associated with josamycin. Therapie 1994; 49: 461–2

    PubMed  CAS  Google Scholar 

  44. Nawaz A, Mohammed I, Ahsan K, et al. Clostridium difficile colitis associated with treatment of Helicobacter pylori infection. Am J Gastroenterol 1998; 93: 1175–6

    Article  PubMed  CAS  Google Scholar 

  45. McKinley M, Toffler RB. Antibiotic associated hemorragic colitis. Dig Dis Sci 1980; 25: 812–3

    Article  PubMed  CAS  Google Scholar 

  46. Blanchi A, Pariente A. Acute hemorrhagic colitis after ingestion of amoxicillin. Gastroenterol Clin Biol 1992; 16: 1012–4

    PubMed  CAS  Google Scholar 

  47. Perez-Castrillon JL, Duenas A, Goyeneche MA, et al. Hemorrhagic colitis due to amoxicillin/clavulanate and nasal decongestants? J Clin Gastroenterol 1997; 25: 701

    Article  PubMed  CAS  Google Scholar 

  48. Fort E, Sevestre C, Cahiez M, et al. Acute hemorrhagic colitis after oral ingestion of synergistin. Gastroenterol Clin Biol 1993; 17: 231–2

    Article  PubMed  CAS  Google Scholar 

  49. Decaux C, Devroede G. Acute colitis related to spiramycin. Lancet 1978; II: 993

    Article  Google Scholar 

  50. David XR, Pierrugues R, Michel H. Acute hemorrhagic colitis related to oral administration of cephalosporin. Gastroenterol Clin Biol 1991; 15: 659

    PubMed  CAS  Google Scholar 

  51. Bellaiche G, Le Pennec MP, Choudat L, et al. Value of rectosigmoidoscopy with bacteriological culture of colonic biopsies in the diagnosis of post-antibiotic hemorrhagic colitis related to Klebsiella oxytoca. Gastroenterol Clin Biol 1997; 21: 764–7

    PubMed  CAS  Google Scholar 

  52. Benoit R, Danchequin Dorval E, Loulergue J, et al. Post-antibiotic diarrheas: role of Klebsiella oxytoca. Gastroenterol Clin Biol 1992; 16: 860–4

    PubMed  CAS  Google Scholar 

  53. Cleau D, humblot S, Jobard JM, et al. Acute right side hemorrhagic colitis with demonstration of Klebsiella oxytoca after treatment with amoxicillin. Presse Med 1994; 23: 1879–80

    PubMed  CAS  Google Scholar 

  54. Danna PL, Urban C, Bellin E, et al. Role of Candida in pathogenesis of antibiotic-associated diarrhea in elderly inpatients. Lancet 1991; 337: 511–4

    Article  PubMed  CAS  Google Scholar 

  55. Dobbins WO, Herrero BA, Mansbach DM. Morphologic alterations associated with neomycin induced malabsorption. Am J Med Sci 1968; 255: 63–7

    Article  PubMed  Google Scholar 

  56. Giannella RA, Serumaga J, Walls D, et al. Effect of clindamycin on intestinal water and glucose transport in the rat. Gastroenterology 1981; 80: 907–13

    PubMed  CAS  Google Scholar 

  57. Weber FH, Richards RD, McCallum RW. Erythromycin: a motilin agonist and gastrointestinal prokinetic agent. Am J Gastroenterol 1993; 88: 485–90

    PubMed  CAS  Google Scholar 

  58. Lees GM, Percy WH. Antibiotic associated colitis: an in vitro investigation of the effects of antibiotics on intestinal motility. Br J Pharmacol 1981; 73: 535–47

    Article  PubMed  CAS  Google Scholar 

  59. Lehtola J, Jaunohen P, Kesaniemi A, et al. Effect of erythromycin on the oro-caecal transit time in man. Eur J Clin Pharmacol 1990; 39: 555–8

    Article  PubMed  CAS  Google Scholar 

  60. Tomosa S, Kuroume T, Arai H, et al. Erythromycin induces migrating motor complex in human gastrointestinal tract. Dig Dis Sci 1986; 31: 157–61

    Article  Google Scholar 

  61. Bjarnason J, MacPherson A. The changing gastrointestinal side effect profile of non steroidal anti-inflammatory drugs. A new approach for the prevention of a new problem. Scand J Gastroenterol 1989; 24: 56–64

    Article  Google Scholar 

  62. Davies NM, Can PD. Toxicity of nonsteroidal anti-inflammatory drugs in the large intestine. Dis Colon Rectum 1995; 38: 1311–21

    Article  PubMed  CAS  Google Scholar 

  63. Morgan GJ, Poland M, DeLapp RE. Efficacy and safety of nabumetone versus diclofenac, naproxen, ibuprofen, and piroxicam in the elderly. Am J Med 1993; 95Suppl. 2A: 19–27

    Article  Google Scholar 

  64. Bjarnason I, Williams P, Smethurst P, et al. Effect of non-steroidal anti-inflammatory drugs and prostaglandins on the permeability of the human small intestine. Gut 1986; 27: 1292–7

    Article  PubMed  CAS  Google Scholar 

  65. Arvanitakis C, Chen GH, Folscroft J, et al. Effects of aspirin on intestinal absorption of glucose, Na and water in man. Gut 1977; 18: 187–90

    Article  PubMed  CAS  Google Scholar 

  66. Lapoile E, Bellaiche G, Nouts A, et al. Pseudomembranous colitis after ingestion of diclofenac. Gastroenterol Clin Biol 1988, 22: 100–1

    Google Scholar 

  67. Gentric A, Pennec YL. Diclofenac induced pseudomembranous colitis. Lancet 1992; 340: 126–7

    Article  PubMed  CAS  Google Scholar 

  68. Kwo PY, Tremaine WJ. Nonsteroidal anti-inflammatory druginduced enteropathy: case discussion and review of the literature. Mayo Clin Proc 1995; 70: 55–61

    PubMed  CAS  Google Scholar 

  69. Bjarnason I, Prouse P, Smith T, et al. Blood and protein loss via small-intestinal inflammation induced by non-steroidal anti-inflammatory drugs. Lancet 1987; II: 711–4

    Article  Google Scholar 

  70. Hall RI, Petty AH, Cobden I, et al. Enteritis and colitis associated with mefenamic acid. BMJ 1983; 287: 1182

    Article  PubMed  CAS  Google Scholar 

  71. Gibson GR, Withacre EB, Ricotti CA. Colitis induced by non-steroidal anti-inflammatory drugs. Arch Intern Med 1992; 152: 625–32

    Article  PubMed  CAS  Google Scholar 

  72. Dao T, Grimaux-Jardin I, Fellous F, et al. Ulcerative colitis secondary to the ingestion of lysine acetylsalicylate. Gastroenterol Clin Biol 1993; 17: 66–7

    PubMed  CAS  Google Scholar 

  73. Sturges HF, Krone CL. Ulceration and stricture of the jejunum in a patient on long-term indomethacin therapy. Am J Gastroenterol 1973; 59: 162–9

    PubMed  CAS  Google Scholar 

  74. Langmann MJS, Morgan L, Worrall A. Use of anti-inflammatory drugs by patients admitted with small or large bowel perforations and haemorrhage. BMJ 1985; 290: 347–9

    Article  Google Scholar 

  75. Bjarnason I, MacPherson AJS. Intestinal toxicity of non-steroidal anti-inflammatory drugs. Pharmacol Ther 1994; 62: 145–57

    Article  PubMed  CAS  Google Scholar 

  76. Kaufmann HJ, Taubin HL. Nonsteroidal anti-inflammatory drugs activate quiescent inflammatory bowel disease. Ann Intern Med 1987; 107: 513–6

    PubMed  CAS  Google Scholar 

  77. Wilson RG, Smith AN, McIntyre IMC. Complications of diverticular disease and non-steroidal anti-inflammatory drugs: a prospective study. Br J Surg 1990; 77: 1103–4

    Article  PubMed  CAS  Google Scholar 

  78. Fang WF, Broughton A, Jacobson ED. Indomethacin-induced intestinal inflammation. Am J Dig Dis 1977; 22: 749–60

    Article  PubMed  CAS  Google Scholar 

  79. Rutherford D, Stockdill G, Hamer-Hodges DW, et al. Proctocolitis induced by salicylate. BMJ 1984; 288: 794

    Article  PubMed  CAS  Google Scholar 

  80. Chakraborty TK, Bhatia D, Heading RC, et al. Salicylate induced exacerbation of ulcerative colitis. Gut 1987; 28: 613–5

    Article  PubMed  CAS  Google Scholar 

  81. Barnejee AK. Enteropathy induced by non-steroidal anti-inflammatory drugs often subclinical but may mimic Crohn’s disease. BMJ 1989; 298: 1539–40

    Article  Google Scholar 

  82. Bridges AJ, Marshall JB, Diaz-Arias AA, et al. Acute eosinophilic colitis and hypersensitivity reaction associated with naproxen therapy. Am J Med 1990; 89: 526–7

    Article  PubMed  CAS  Google Scholar 

  83. Guedon C, Bruna T, Ducrotte P, et al. Severe diarrhea caused by Ticlid associated with disorders of small intestine motility. Gastroenterol Clin Biol 1989; 13: 934–7

    PubMed  CAS  Google Scholar 

  84. Giardina MG, Matarazzo M, Cacciatore L, et al. Ticlopidine can cause chronic diarrhea. Lancet 1984; I: 407

    Article  Google Scholar 

  85. Chassany O, Bacq Y, Metman EH, et al. Severe chronic diarrhea during treatment with ticlopidine. Gastroenterol Clin Biol 1989; 13: 950

    PubMed  CAS  Google Scholar 

  86. Fraga MD, Garcia B, Agud JL, et al. Severe chronic diarrhea induced by ticlopidine. Ann Pharmacother 1996; 30: 1496

    PubMed  CAS  Google Scholar 

  87. Mansoor GA, Aziz K. Delayed chronic diarrhea and weight loss possibly due to ticlopidine therapy. Ann Pharmacother 1997; 31: 870–2

    PubMed  CAS  Google Scholar 

  88. Ruget O, Burtin P, Cerz H, et al. Chronic diarrhea associated with villous atrophy and lymphocytic gastritis caused by ticlopidine. Gastroenterol Clin Biol 1992; 16: 290

    PubMed  CAS  Google Scholar 

  89. Swine C, Cornette P, Van Pee D, et al. Ticlopidine, diarrhea and lymphocytic colitis. Gastroenterol Clin Biol 1998; 22: 475–6

    PubMed  CAS  Google Scholar 

  90. Brigot C, Courillon-Mallet A, Roucayrol AM, et al. Lymphocytic colitis and ticlopidine. Gastroenterol Clin Biol 1998; 22: 361–2

    PubMed  CAS  Google Scholar 

  91. Martinez Aviles P, Gisbert-Moya C, Berbegal-Serra J, et al. Ticlopidine-induced lymphocytic colitis. Med Clin Barc 1996; 106: 307

    Google Scholar 

  92. Cohen IS, Jick H, Cohen SI, et al. Adverse reactions to quinidine in hospitalized patients: findings based on data from the Boston Collaborative Drug Surveillance Program. Prog Cardiovasc Dis 1977; 20: 152–63

    Article  Google Scholar 

  93. Auricchio RJ. Cardiac arrhythmias. In: Young LY, Koda-Kimble MA, editors. Applied therapeutics: the clinical use of drugs, 4th ed. Vancouver: Applied Therapeutics, 1988

    Google Scholar 

  94. Romankiewicz JA, Reidenberg M, Drayer D, et al. The noninterference of aluminium hydroxide gel with quinidine sulphate absorption: an approach to control quinidine-induced diarrhea. Am Heart J 1978; 96: 518–20

    Article  PubMed  CAS  Google Scholar 

  95. Rudusky BM. Cholestyramine therapy for quinidine-induced diarrhea. Case reports. Angiology 1997; 48: 173–6

    Article  PubMed  CAS  Google Scholar 

  96. Horvath F, Marbury TC, Uhlemann ER, et al. Severe diarrhea secondary to propranolol. South Med 1979; 72: 367–8

    Article  Google Scholar 

  97. Robinson JD, Burtner DE. Severe diarrhea secondary to propranolol. Drug Intell Clin Pharm 1981; 15: 49–50

    PubMed  CAS  Google Scholar 

  98. Rolachon A, Bichard P, Kezachian G, et al. Chronic diarrhea caused by isradipine. Gastroenterol Clin Biol 1993; 17: 310–1

    PubMed  CAS  Google Scholar 

  99. Hedner T. Calcium channel blockers: spectrum of side effects and drug interactions. Acta Pharmacol Toxicol 1986; 58Suppl. 2: 119–30

    CAS  Google Scholar 

  100. Quart BD, Guglielmo BJ. Prolonged diarrhea secondary to methyldopa therapy. Drug Intell Clin Pharm 1983; 17: 462

    PubMed  CAS  Google Scholar 

  101. Gloth FM, Busby MJ. Methyldopa-induced diarrhea: case of iatrogenic diarrhea leading to request for nursing home replacement. Am J Med 1989; 87: 480–1

    Article  PubMed  Google Scholar 

  102. Graham CF, Gallagher K, Jones JK. Acute colitis with methyldopa. N Engl J Med 1981; 304: 1044–5

    PubMed  CAS  Google Scholar 

  103. Shneerson JM, Gazzard BJ. Reversible malabsorption caused by methyldopa. BMJ 1977; 2: 1456–7

    Article  PubMed  CAS  Google Scholar 

  104. Mahdyoon H, Battilana G, Rosman H, et al. The evolving pattern of digoxin intoxication: observations at a large urban hospital from 1980-1988. Am Heart J 1990; 120: 1189–94

    Article  PubMed  CAS  Google Scholar 

  105. Andrews PA, Wilkinson PR. Diarrhoea as a side effect of digoxin. BMJ 1990; 301: 1398

    Article  PubMed  CAS  Google Scholar 

  106. Bourhis T, Riard P, Danel V, et al. Digitalis poisoning with severe ischemic colitis: a favorable course after treatment with specific antibodies. Gastroenterol Clin Biol 1990; 14: 95

    PubMed  CAS  Google Scholar 

  107. Bouaniche M, Chassagne P, Landrin I, et al. Lymphocytic colitis caused by Cyclo 3 Fort. Rev Med Int 1996; 17: 776–8

    Article  CAS  Google Scholar 

  108. Thomas-Anterion C, Guy C, Vial F, et al. Unexplained chronic diarrhea. A propos of 4 new cases under Cyclo 3 Fort and review of the literature. Rev Med Interne 1993; 14: 215–7

    Article  PubMed  CAS  Google Scholar 

  109. Ouyahya F, Codjovi P, Machet MC, et al. Diarrhea induced by Cyclo 3 Fort and lymphocytic colitis. Gastroenterol Clin Biol 1993; 17: 65–6

    PubMed  CAS  Google Scholar 

  110. Pierrugues R, Saingra B. Lymphocytic colitis and Cyclo 3 Fort: 4 new cases. Gastroenterol Clin Biol 1996; 20: 916–7

    PubMed  CAS  Google Scholar 

  111. Maechel H. Cirkan-induced chronic diarrhea. Gastroenterol Clin Biol 1992; 16: 373

    PubMed  CAS  Google Scholar 

  112. Raoul JL, Dautreme S, Heresbach N, et al. Chronic diarrhea during treatment with Veinotonyl 75. Ann Gastroenterol Hepatol 1994; 30: 25

    CAS  Google Scholar 

  113. Hastier P, Bianchi D, Chichmanian RM, et al. Chronic diarrhea secondary to Veinamitol. Therapie 1994; 49: 148–9

    PubMed  CAS  Google Scholar 

  114. Widgren S, de Peyer R, Geissbuhler P, et al. Enterocolitis due to a saponin-containing drug. A propos of a case. Schweiz Med Wochenschr 1994; 124: 313–8

    PubMed  CAS  Google Scholar 

  115. Piper DW. A comparative overview of the adverse effects of antiulcer drugs. Drug Saf 1995; 12: 120–38

    Article  PubMed  CAS  Google Scholar 

  116. Yen L. Cimetidine-induced diarrhea. Drug Intell Clin Pharm 1985; 19: 185

    Google Scholar 

  117. Beaugerie L, Patey N, Brousse N. Ranitidine, diarrhea, and lymphocytic colitis. Gut 1995; 37: 708–11

    Article  PubMed  CAS  Google Scholar 

  118. Beaugerie L, Berrebi D, Dikov D, et al. Epithelial apoptosis a very early marker of drug-induced colitis. The example of ranitidine. Gastroenterol Clin Biol 1996; 20: 918–9

    CAS  Google Scholar 

  119. Duncan HD, Talbot IC, Silk DB. Collagenous colitis and cimetidine. Eur J Gastroenterol Hepatol 1997; 9: 819–20

    Article  PubMed  CAS  Google Scholar 

  120. Field R, Meyer GW. Diarrhea from cimetidine. N Engl J Med 1978; 299: 262

    PubMed  CAS  Google Scholar 

  121. Leufkens H, Claessens A, Heerdink E, et al. A prospective follow-up study of 5669 users of lansoprazole in daily practice. Aliment Pharmacol Ther 1997; 11: 887–97

    Article  PubMed  CAS  Google Scholar 

  122. Rachmilewitz D. Prostaglandins and diarrhea. Dig Dis Sci 1980; 25: 897–8

    Article  PubMed  CAS  Google Scholar 

  123. Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. Ann Intern Med 1995; 123: 241–9

    PubMed  CAS  Google Scholar 

  124. Graham DY, White RH, Moreland LW, et al. Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs. Ann Intern Med 1993; 119: 257–62

    PubMed  CAS  Google Scholar 

  125. Herting RL, Clay GA. Overview of clinical safety with misoprostol. Dig Dis Sci 1985; 30Suppl.: 185S–93S

    Article  PubMed  CAS  Google Scholar 

  126. Bocanegra TS, Weaver AL, Tindall EA, et al. Diclofenac/misoprostol compared with diclofenac in the treatment of osteoarthritis of the knee or hip: a randomized, placebo controlled trial. Arthrotec osteoarthritis study group. J Rheumatol 1998; 25: 1602–11

    PubMed  CAS  Google Scholar 

  127. Gagnier P. Review of the safety of diclofenac/misoprostol. Drugs 1993; 45Suppl.: 31–5

    Article  PubMed  Google Scholar 

  128. Davis R, Yarker YE, Goa KL. Diclofenac/misoprostol: a review of its pharmacology and therapeutic efficacy in painful inflammatory conditions. Drugs Aging 1995; 7: 372–93

    Article  PubMed  CAS  Google Scholar 

  129. Melo Gomes JA, Roth SH, Zeeh J, et al. Double-blind comparison of efficacy and gastroduodenal safety of diclofenac/misoprostol, piroxicam, and naproxen in the treatment of osteoarthritis. Ann Rheum Dis 1993; 52: 881–5

    Article  PubMed  CAS  Google Scholar 

  130. Bright-Asare P. Treatment of duodenal ulcer with enprostil, a prostaglandin E2 analog. Am J Med 1986; 81: 64–8

    Article  PubMed  CAS  Google Scholar 

  131. Jain JK, Mishell DR. A comparison of intravaginal misoprostol with prostaglandin E2 for termination of second-trimester pregnancy. N Engl J Med 1994; 331: 290–3

    Article  PubMed  CAS  Google Scholar 

  132. Castell DO, Sigmund C, Patterson D, et al. Cisapride 20 mg b.i.d. provides symptomatic relief of heartburn and related symptoms of chronic mild to moderate gastroesophageal reflux disease. CIS-USA-52 investigator group. Am J Gastroenterol 1998; 93: 547–52

    Article  PubMed  CAS  Google Scholar 

  133. Wiseman LR, Faulds D. Cisapride. An updated review of its pharmacology and therapeutic efficacy as a prokinetic agent in gastrointestinal motility disorders. Drugs 1994; 47: 116–52

    Article  PubMed  CAS  Google Scholar 

  134. Nguyen M, Dougados M, Berdah L, et al. Diacerhein in the treatment of osteoarthritis of the hip. Arthritis Rheum 1994; 37: 529–36

    Article  PubMed  CAS  Google Scholar 

  135. Blondon H, Bikart I, Bergmann JF. Severe diarrhea with hypokalemia attributed to diacetylrhein. Gastroenterol Clin Biol 1995; 19: 851–2

    PubMed  CAS  Google Scholar 

  136. Verne GN, Eaker EY, Davis RH, et al. Colchicine is an effective treatment for patients with chronic constipation: an openlabel trial. Dig Dis Sci 1997; 42: 1959–63

    Article  PubMed  CAS  Google Scholar 

  137. Ehrenfeld M, Levy M, Sharon P, et al. Gastrointestinal effects of long-term colchicine therapy in patients with recurrent polyserositis (familial Mediterranean fever). Dig Dis Sci 1982; 27: 723–7

    Article  PubMed  CAS  Google Scholar 

  138. Fradkin A, Yahav J, Zemer D, et al. Colchicine-induced lactose malabsorption in patients with familial Mediterranean fever. Isr J Med Sci 1995; 31: 616–20

    PubMed  CAS  Google Scholar 

  139. Chen B, Shapira J, Ravid M, et al. Steatorrhea induced by allopurinol. BMJ 1982; 284: 1914

    Article  PubMed  CAS  Google Scholar 

  140. Furst DE. Mechanism of action, pharmacology, clinical efficacy and side effects of auranofin. An orally administered organic gold compound for the treatment of rheumatoid arthritis. Pharmacotherapy 1983; 3: 284–98

    PubMed  CAS  Google Scholar 

  141. Wallin BA, McCafferty JP, Fox MJ, et al. Incidence and management of diarrhea during long term auranofin therapy. J Rheumatol 1988; 15: 1755–8

    PubMed  CAS  Google Scholar 

  142. Magaro M, Altomonte L, Mirone L, et al. Effect of oral gold salt therapy on bile acid absorption in rheumatoid arthritis patients. Clin Rheumatol 1990; 9: 42–7

    Article  PubMed  CAS  Google Scholar 

  143. Gerster JC, Kalbermatten A, Peyer R, et al. Toxic reactions to gold salts with severe enterocolitis in a patient with rheumatoid arthritis. Schweiz Med Wochenschr 1976; 106: 1606–8

    PubMed  CAS  Google Scholar 

  144. Jackson CW, Haboubi NY, Whorwell PJ, et al. Gold induced enterocolitis. Gut 1986; 27: 452–6

    Article  PubMed  CAS  Google Scholar 

  145. Bross-Bach U, Saal JG, Hartmann F, et al. Ulcerative colitis caused by oral gold therapy in rheumatoid arthritis. Z Rheumatol 1987; 46: 201–4

    PubMed  CAS  Google Scholar 

  146. Marcuard SP, Ehrinpreis MN, Fitter WF. Gold induced ulcerative proctitis: report and review of the literature. J Rheumatol 1987; 14: 142–4

    PubMed  CAS  Google Scholar 

  147. Evron E, Brautbar C, Becker S, et al. Correlation between goldinduced enterocolitis and the presence of the HLADRB1* 0404 allele. Arthritis Rheum 1995; 38: 755–9

    Article  PubMed  CAS  Google Scholar 

  148. Pitt P, Berry H. Fluoride treatment in osteoporosis. Postgrad Med J 1991; 67: 323–6

    Article  PubMed  CAS  Google Scholar 

  149. Pak CY, Sakhaee K, Gallagher C, et al. Attainment of therapeutic fluoride levels in serum without major side effects using a slow-release preparation of sodium fluoride in postmenopausal osteoporosis. J Bone Miner Res 1986; 1: 563–71

    Article  PubMed  CAS  Google Scholar 

  150. Gray TK, Brannan P, Juan D, et al. Ion transport changes during calcitonin-induced intestinal secretion in man. Gastroenterology 1976; 71: 392–8

    PubMed  CAS  Google Scholar 

  151. Zorzin L, Capone M. Postmenopausal osteoporosis: therapeutic and side effects of different calcitonins. Curr Ther Res 1984; 36: 473–82

    Google Scholar 

  152. Luzzani M, Vidili MG, Rissotto R, et al. Disodium clodronate in the treatment of pain due to bone metastases. Int J Clin Pharm Res 1990; 10: 243–6

    CAS  Google Scholar 

  153. Khairi MR, Altman RD, DeRosa GP, et al. Sodium etidronate in the treatment of Paget’s disease of bone. A study of longterm results. Ann Intern Med 1977; 87: 656–63

    PubMed  CAS  Google Scholar 

  154. Federlin KF, Mehlburger L, Hillebrand I, et al. The effect of two new glucosidase inhibitors on blood glucose in healthy volunteers and in type 2 diabetics. Acta Diabetol Lat 1987; 24: 213–21

    Article  PubMed  CAS  Google Scholar 

  155. Hollander P. Safety profile of acarbose, an alpha-glucosidase inhibitor. Drugs 1992; 44Suppl. 2: 47–53

    Article  PubMed  Google Scholar 

  156. Johnston PS, Feig PU, Coniff RF, et al. Long-term titrated-dose alpha-glucosidase inhibitor in non-insulin-requiring Hispanic NIDDM patients. diabetes Care 1998; 21: 409–15

    Article  PubMed  CAS  Google Scholar 

  157. Melchior WR, Jaber LA. Metformin: an antihyperglycemic agent for treatment of type 2 diabetes. Ann Pharmacother 1996; 30: 158–64

    PubMed  CAS  Google Scholar 

  158. McGuinness ME, Talbert RL. Phenformin-induced lactic acidosis: a forgotten adverse drug reaction. Ann Pharmacother 1993; 27: 1183–7

    PubMed  CAS  Google Scholar 

  159. Curry CE, Tatum-Butler D. Laxative products. In: Covington TR, editor. Handbook of nonprescription drugs, 10th ed. Washington, DC: American Pharmaceutical Association, 1993: 219–33

    Google Scholar 

  160. Chusid MJ, Chusid JA. Diarrhea induced by sorbitol. J Pediatr 1981; 99: 326

    PubMed  CAS  Google Scholar 

  161. Hammer HF, Santa Ana CA, Schiller LR, et al. Studies of osmotic diarrhea induced in normal subjects by ingestion of polyethylene glycol and lactulose. J Clin Invest 1989; 84: 1056–62

    Article  PubMed  CAS  Google Scholar 

  162. Reele SB, Chodos DJ. Sorbitol induced diarrheal illness model. Int J Clin Pharmacol Ther Toxicol 1985; 23: 403–5

    PubMed  CAS  Google Scholar 

  163. Strom M. Antacid side-effects on bowel habits. Scand J Gastroenterol 1982; 17Suppl. 75: 54–5

    Google Scholar 

  164. Anonymous. Senna and pseudomelanosis coli. Pharmacology 1992; 44 Suppl. 1:33–5

  165. Nataf C, Desmazures C, Giraudeaux V, et al. Laxative-induced intestinal protein loss in normal subjects. Gastroenterol Clin Biol 1981; 5: 187–92

    PubMed  CAS  Google Scholar 

  166. Scheurlen C, Allgayer H, Kruis W, et al. Effect of olsalazine and mesalazine on human ileal and colonic (Na+/K+)-ATPase. A possible diarrhogenic factor? Clin Invest 1993; 71: 286–9

    Article  CAS  Google Scholar 

  167. Wright JP, O’Keefe EA, Cuming L, et al. Olsalazine in maintenance of clinical remission in patients with ulcerative colitis. Dig Dis Sci 1993; 38: 1837–42

    Article  PubMed  CAS  Google Scholar 

  168. Chawla A, Karl PI, Reich RN, et al. Effect of olsalazine on sodium-dependent bile acid transport in rat ileum. Dig Dis Sci 1995; 40: 943–8

    Article  PubMed  CAS  Google Scholar 

  169. Pamukcu R, Hanauer SB, Chang EB. Effect of disodium azodisalicylate on electrolyte transport in rabbit ileum and colon in vitro. Comparison with sulfasalazine and 5-aminosalicylic acid. Gastroenterology 1988; 95: 975–81

    PubMed  CAS  Google Scholar 

  170. Travis SP, Tysk C, de Silva HJ, et al. Optimum dose of olsalazine for maintaining remission in ulcerative colitis. Gut 1994; 35: 1282–6

    Article  PubMed  CAS  Google Scholar 

  171. Martenson JA, Hyland G, Moertel CG, et al. Olsalazine is contraindicated during pelvic radiation therapy: results of a double-blind, randomized clinical trial. Int J Radiat Oncol Biol Phys 1996; 35: 299–303

    Article  PubMed  CAS  Google Scholar 

  172. Raimundo AH, Patil DH, Frost PG, et al. Effects of olsalazine and sulphasalazine on jejunal and ileal water and electrolyte absorption in normal human subjects. Gut 1991; 32: 270–74

    Article  PubMed  CAS  Google Scholar 

  173. Kruis W, Judmaier G, Kayasseh L, et al. Double-blind dosefinding study of olsalazine versus sulphasalazine as maintenance therapy for ulcerative colitis. Eur J Gastroenterol Hepatol 1995; 7: 391–6

    PubMed  CAS  Google Scholar 

  174. Nilsson A, Danielsson A, Lofberg R, et al. Olsalazine versus sulphasalazine for relapse prevention in ulcerative colitis: a multicenter study. Am J Gastroenterol 1995; 90: 381–7

    PubMed  CAS  Google Scholar 

  175. Van Gaal LF, Broom JI, Enzi G, et al. Efficacy and tolerability of orlistat in the treatment of obesity: a 6-month dose-ranging study. Eur J Clin Pharmacol 1998; 54: 125–32

    Article  PubMed  Google Scholar 

  176. Sjôstrôm L, Rissanen A, Andersen T, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet 1998; 352: 167–73

    Article  PubMed  Google Scholar 

  177. McNeely W, Benfield P. Orlistat. Drugs 1998; 56: 241–9

    Article  PubMed  CAS  Google Scholar 

  178. Bow EJ, Gallant GJ, Woloschuk D, et al. Remission induction therapy of untreated acute myeloid leukemia using a noncytarabine-containing regimen of idarubicin, etoposide, and carboplatin. Cancer 1998; 83: 1344–54

    Article  PubMed  CAS  Google Scholar 

  179. Cascinu S, Fedeli A, Fedeli SL, et al. Octreotide versus loperamide in the treatment of fluorouracil-induced diarrhea: a randomized trial. J Clin Oncol 1993; 11: 148–51

    PubMed  CAS  Google Scholar 

  180. Jarvis B, Shevchuk YM. Recurrent Clostridium difficile diarrhea associated with mitoxantrone and etoposide: a case report and review. Pharmacotherapy 1997; 17: 606–11

    PubMed  CAS  Google Scholar 

  181. Anand A, Glatt AE. Clostridium difficile infection associated with antineoplastic chemotherapy: a review. Clin Infect Dis 1993; 17: 109–13

    Article  PubMed  CAS  Google Scholar 

  182. Husain A, Aptaker L, Spriggs DR, et al. Gastrointestinal toxicity and Clostridium difficile diarrhea in patients treated with paclitaxel-containing chemotherapy regimens. Gynecol Oncol 1998: 71: 104–7

    Article  PubMed  CAS  Google Scholar 

  183. Cudmore MA, Silva J, Fekety R, et al. Clostridium difficile colitis associated with cancer chemotherapy. Arch Intern Med 1982; 142: 333–5

    PubMed  CAS  Google Scholar 

  184. Jackson IM, Barnard LB, Lamberton P. Role of a long-acting somatostatin analogue (SMS 201-995) in the treatment of acromegaly. Am J Med 1986; 81: 94–101

    Article  PubMed  CAS  Google Scholar 

  185. Ho PJ, Boyaji LD, Greenstein E, et al. Effect of chronic octreotide treatment on intestinal absorption in patients with acromegaly. Dig Dis Sci 1993; 38: 309–15

    Article  PubMed  CAS  Google Scholar 

  186. Nakamura T, Kudoh K, Takebe K, et al. Octreotide decreases biliary and pancreatic exocrine function, and induces steatorrhea in healthy subjects. Intern Med 1994; 33: 593–6

    Article  PubMed  CAS  Google Scholar 

  187. Kuhn JM, Legrand A, Ruiz JM, et al. Pharmacokinetic and pharmacodynamic properties of a long-acting formulation of the new somatostatin analogue, lanreotide, in normal healthy volunteers. Br J Clin Pharmacol 1994; 38: 213–9

    Article  PubMed  CAS  Google Scholar 

  188. Maton PN, Iser JH, Reuben A, et al. Outcome of chenodeoxycholic acid (CDCA) treatment in 125 patients with radiolucent gallstones. Medicine 1982; 61: 86–97

    Article  PubMed  CAS  Google Scholar 

  189. Kruis W, Haddad A, Phillips SF. Chenodeoxycholic and ursodeoxycholic acids alter motility and fluid transit in the canine ileum. Digestion 1986; 34: 185–95

    Article  PubMed  CAS  Google Scholar 

  190. Sackmann M, Paulezki J, Aydemir U, et al. Efficacy and safety of ursodeoxycholic acid for dissolution of gallstone fragments: comparison with the combination of ursodeoxycholic acid and chenodeoxycholic acid. Hepatology 1991; 14: 1136–41

    PubMed  CAS  Google Scholar 

  191. Knodel LC, Talbert RL. Adverse effects of hypolipidaemic drugs. Med Toxicol 1987; 2: 10–32

    PubMed  CAS  Google Scholar 

  192. Lane R, Baldwin D. Selective serotonin reuptake inhibitor-induced serotonin syndrome: review. J Clin Psychopharmacol 1997; 17: 208–21

    Article  PubMed  CAS  Google Scholar 

  193. Gracon SI, Knapp MJ, Berghoff WG, et al. Safety of tacrine: clinical trials, treatment IND, and postmarketing experience. Alzheimer Dis Assoc Disord 1998; 12: 93–101

    Article  PubMed  CAS  Google Scholar 

  194. Rogers SL, Doody RS, Mohs RC, et al. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil study group. Arch Intern Med 1998; 158: 1021–31

    Article  PubMed  CAS  Google Scholar 

  195. Antuono PG. Effectiveness and safety of velnacrine for the treatment of Alzheimer’s disease. A double-blind, placebo-controlled study. Mentane study group. Arch Intern Med 1995; 155: 1766–72

    Article  PubMed  CAS  Google Scholar 

  196. Bever KA, Perrry PJ. Dexfenfluramine hydrochloride: an anorexigenic agent. Am J Health Syst Pharm 1997; 54: 2059–72

    PubMed  CAS  Google Scholar 

  197. Wagner ML, Landis BE. Riluzole: a new agent for amyotrophic lateral sclerosis. Ann Pharmacother 1997; 31: 738–44

    PubMed  CAS  Google Scholar 

  198. Waters CH, Kurth M, Bailey P, et al. Tolcapone in stable Parkinson’s disease: efficacy and safety of long-term treatment. Tolcapone stable study group. Neurology 1998; 50Suppl. 5: 39–45

    Article  Google Scholar 

  199. Labayle D, Delas N, Pariente A, et al. Severe psychiatric disorders associated with severe acute colitis. Gastroenterol Clin Biol 1992; 16: 639–43

    PubMed  CAS  Google Scholar 

  200. Basse P. Ischemic colitis complicating imipramine overdose and alcohol ingestion. Eur J Surg 1992; 158: 187–8

    PubMed  CAS  Google Scholar 

  201. Meya U, Moller B, Renfordt E, et al. A case of perazine-induced enteritis. Allergy or pseudoallergy? Pharmacopsychiatry 1985; 18: 263–6

    Article  PubMed  CAS  Google Scholar 

  202. Mahajan L, Wyllie R, Goldblum J. Lymphocytic colitis in a pediatric patient: a possible adverse reaction to carbamazepine. Am J Gastroenterol 1997; 92: 2126–7

    PubMed  CAS  Google Scholar 

  203. Chauveau E, Prignet JM, Carloz E, et al. Lymphocytic colitis secondary to ingestion of vinburnine (Cervoxan). Gastroenterol Clin Biol 1998; 22: 362

    PubMed  CAS  Google Scholar 

  204. Martin P, Manley PN, Depew WT, et al. Isotretinoin-associated proctosigmoiditis. Gastroenterology 1987; 93: 606–9

    PubMed  CAS  Google Scholar 

  205. Cox J, Daneshmend TK, Hawkey CJ, et al. Devastating diarrhea caused by azathioprine: management difficulty in inflammatory bowel disease. Gut 1988; 29: 686–8

    Article  PubMed  CAS  Google Scholar 

  206. Murphy EA, Morris AJ, Walker E, et al. Cyclosporine Ainduced colitis and acquired selective IgA deficiency in a patient with juvenile chronic arthritis. J Rheumatol 1993; 20: 1397–8

    PubMed  CAS  Google Scholar 

  207. Bowen JR, Sahi S. Cyclosporin induced colitis. BMJ 1993; 307: 484

    Article  PubMed  CAS  Google Scholar 

  208. Pike IM, Nicaise C. The didanosine expanded access program: safety analysis. Clin Infect Dis 1993; 16Suppl. 1: 63–8

    Article  Google Scholar 

  209. Lieb J, Kazienko DJ. Lactose filler as a cause of ‘drug-induced’ diarrhea. N Engl J Med 1978; 299: 314

    PubMed  CAS  Google Scholar 

  210. Shelly MS. Iatrogenic diarrhea caused by sorbitol. J Fam Pract 1993; 36: 95–6

    PubMed  CAS  Google Scholar 

  211. Hill DB, Henderson LM, McClain CJ. Osmotic diarrhea induced by sugar-free theophylline solution in critically ill patients. J Parenter Enterol Nutr 1991; 15: 332–6

    Article  CAS  Google Scholar 

  212. Spreux A, Rodriguez A, Chichmanian RM. Case reports on drug-induced chronic diarrhea. An often unrecognized etiology? Therapie 1993; 48: 494–5

    PubMed  CAS  Google Scholar 

  213. Talal AH, Murray JA. Acute and chronic diarrhea. How to keep laboratory testing to a minimum. Postgrad Med 1994; 96: 30–8

    PubMed  CAS  Google Scholar 

  214. Bennett RG, Greenough WB. Approach to acute diarrhea in the elderly. Gastroenterol Clin North Am 1993; 22: 517–33

    PubMed  CAS  Google Scholar 

  215. Donowitz M, Kokke FT, Saidi R. Evaluation of patients with chronic diarrhea. N Engl J Med 1995; 332: 725–9

    Article  PubMed  CAS  Google Scholar 

  216. Duncan A, Cameron A, Stewart MJ, et al. Diagnosis of the abuse of magnesium and stimulant laxatives. Ann Clin Biochem 1991; 28: 568–73

    PubMed  Google Scholar 

  217. Read NW, Krjs GJ, Read MG, et al. Chronic diarrhea of unknown origin. Gastroenterology 1980; 78: 264–71

    PubMed  CAS  Google Scholar 

  218. Wenisch C, Parschalk B, Hasenhundl M, et al. Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea. Clin Infect Dis 1996; 22: 813–8

    Article  PubMed  CAS  Google Scholar 

  219. Hospital Infection Control Advisory Committee. Recommendations for preventing the spread of vancomycin-resistant enterococci. Am J Infect Control 1995; 23: 87–94

    Google Scholar 

  220. Fekety R, McFarland LV, Surawicz CM, et al. Recurrent Clostridium difficile diarrhea: characteristics of and risk factors for patients enrolled in a prospective, randomized, double-blinded trial. Clin Infect Dis 1997; 24: 324–33

    Article  PubMed  CAS  Google Scholar 

  221. Lewis SJ, Freedman AR. Review article: the use of biotherapeutic agents in the prevention and treatment of gastrointestinal disease. Aliment Pharmacol Ther 1998; 12: 807–22

    Article  PubMed  CAS  Google Scholar 

  222. Lewis SJ, Potts LF, Barry RE. The lack of therapeutic effect of Saccharomyces boulardii in the prevention of antibiotic-related diarrhoea in elderly patients. J Infect 1998; 36: 171–4

    Article  PubMed  CAS  Google Scholar 

  223. McFarland LV, Surawicz CM, Greenberg RN, et al. Arandomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 1994; 271: 1913–8

    Article  PubMed  CAS  Google Scholar 

  224. Fredenucci I, Chomarat M, Boucaud C, et al. Saccharomyces boulardii fungemia in a patient receiving Ultra-levure therapy. Clin Infect Dis 1998; 27: 222–3

    Article  PubMed  CAS  Google Scholar 

  225. Viggiano M, Badetti C, Bernini V, et al. Saccharomyces boulardii fungemia in a patient with severe burns. Ann Fr Anesth Reanim 1995; 14: 356–8

    Article  PubMed  CAS  Google Scholar 

  226. Bassetti S, Frei R, Zimmerli W. Fungemia with Saccharomyces cerevisiae after treatment with Saccharomyces boulardii. Am J Med 1998; 105: 71–2

    Article  PubMed  CAS  Google Scholar 

  227. McCullough MJ, Clemons KV, McCusker JH, et al. Species identification and virulence attributes of Saccharomyces boulardii (nom. inval.). J Clin Microbiol 1998; 36: 2613–7

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Olivier Chassany.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chassany, O., Michaux, A. & Bergmann, J.F. Drug-Induced Diarrhoea. Drug-Safety 22, 53–72 (2000). https://doi.org/10.2165/00002018-200022010-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-200022010-00005

Keywords

Navigation